Targeting angiogenesis in gastrointestinal tumors: Current challenges

Amara G. Nandikolla, Lakshmi Rajdev

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Colorectal cancer (CRC) is one of the few cancers where screening modalities are standardized, but it still remains the third leading cause of cancer related mortality. For more than a decade now, the approval of anti-angiogenic therapy has led to an increase in the rate of overall survival (OS) of patients with advanced colon cancer. The drawback of the anti-angiogenic therapy is that their effect is short-lived and many patients progress through these therapies. Various mechanisms of resistance have been hypothesized, but overcoming this has been challenging. Also, there are no standardized predictive biomarkers that could aid in selecting patients who responds to the therapy upfront. This review focuses on the basis of angiogenesis, describing the approved anti-angiogenic therapies, discusses the challenges in terms of resistance to anti-angiogenic therapy and also the role of biomarkers. In the future, hopefully newer targeted therapies, immunotherapy, combination therapies and the standardization of biomarkers may result in improved outcomes and cure rates.

Original languageEnglish (US)
Article number67
JournalTranslational Gastroenterology and Hepatology
Volume2016
Issue numberSEP
DOIs
StatePublished - 2016

Fingerprint

Neoplasms
Biomarkers
Therapeutics
Early Detection of Cancer
Immunotherapy
Colonic Neoplasms
Colorectal Neoplasms
Survival Rate
Mortality

Keywords

  • Anti-angiogenic agents
  • Biomarkers
  • Challenges
  • Colorectal cancer (CRC)
  • Resistance

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Targeting angiogenesis in gastrointestinal tumors : Current challenges. / Nandikolla, Amara G.; Rajdev, Lakshmi.

In: Translational Gastroenterology and Hepatology, Vol. 2016, No. SEP, 67, 2016.

Research output: Contribution to journalReview article

@article{e4c9b65af46e4c68b013ec268e524b38,
title = "Targeting angiogenesis in gastrointestinal tumors: Current challenges",
abstract = "Colorectal cancer (CRC) is one of the few cancers where screening modalities are standardized, but it still remains the third leading cause of cancer related mortality. For more than a decade now, the approval of anti-angiogenic therapy has led to an increase in the rate of overall survival (OS) of patients with advanced colon cancer. The drawback of the anti-angiogenic therapy is that their effect is short-lived and many patients progress through these therapies. Various mechanisms of resistance have been hypothesized, but overcoming this has been challenging. Also, there are no standardized predictive biomarkers that could aid in selecting patients who responds to the therapy upfront. This review focuses on the basis of angiogenesis, describing the approved anti-angiogenic therapies, discusses the challenges in terms of resistance to anti-angiogenic therapy and also the role of biomarkers. In the future, hopefully newer targeted therapies, immunotherapy, combination therapies and the standardization of biomarkers may result in improved outcomes and cure rates.",
keywords = "Anti-angiogenic agents, Biomarkers, Challenges, Colorectal cancer (CRC), Resistance",
author = "Nandikolla, {Amara G.} and Lakshmi Rajdev",
year = "2016",
doi = "10.21037/tgh.2016.08.04",
language = "English (US)",
volume = "2016",
journal = "Translational Gastroenterology and Hepatology",
issn = "2224-476X",
publisher = "AME Publishing Company",
number = "SEP",

}

TY - JOUR

T1 - Targeting angiogenesis in gastrointestinal tumors

T2 - Current challenges

AU - Nandikolla, Amara G.

AU - Rajdev, Lakshmi

PY - 2016

Y1 - 2016

N2 - Colorectal cancer (CRC) is one of the few cancers where screening modalities are standardized, but it still remains the third leading cause of cancer related mortality. For more than a decade now, the approval of anti-angiogenic therapy has led to an increase in the rate of overall survival (OS) of patients with advanced colon cancer. The drawback of the anti-angiogenic therapy is that their effect is short-lived and many patients progress through these therapies. Various mechanisms of resistance have been hypothesized, but overcoming this has been challenging. Also, there are no standardized predictive biomarkers that could aid in selecting patients who responds to the therapy upfront. This review focuses on the basis of angiogenesis, describing the approved anti-angiogenic therapies, discusses the challenges in terms of resistance to anti-angiogenic therapy and also the role of biomarkers. In the future, hopefully newer targeted therapies, immunotherapy, combination therapies and the standardization of biomarkers may result in improved outcomes and cure rates.

AB - Colorectal cancer (CRC) is one of the few cancers where screening modalities are standardized, but it still remains the third leading cause of cancer related mortality. For more than a decade now, the approval of anti-angiogenic therapy has led to an increase in the rate of overall survival (OS) of patients with advanced colon cancer. The drawback of the anti-angiogenic therapy is that their effect is short-lived and many patients progress through these therapies. Various mechanisms of resistance have been hypothesized, but overcoming this has been challenging. Also, there are no standardized predictive biomarkers that could aid in selecting patients who responds to the therapy upfront. This review focuses on the basis of angiogenesis, describing the approved anti-angiogenic therapies, discusses the challenges in terms of resistance to anti-angiogenic therapy and also the role of biomarkers. In the future, hopefully newer targeted therapies, immunotherapy, combination therapies and the standardization of biomarkers may result in improved outcomes and cure rates.

KW - Anti-angiogenic agents

KW - Biomarkers

KW - Challenges

KW - Colorectal cancer (CRC)

KW - Resistance

UR - http://www.scopus.com/inward/record.url?scp=85007143686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007143686&partnerID=8YFLogxK

U2 - 10.21037/tgh.2016.08.04

DO - 10.21037/tgh.2016.08.04

M3 - Review article

AN - SCOPUS:85007143686

VL - 2016

JO - Translational Gastroenterology and Hepatology

JF - Translational Gastroenterology and Hepatology

SN - 2224-476X

IS - SEP

M1 - 67

ER -